Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcElvaney, N.en
dc.contributor.authorBurdon, J.en
dc.contributor.authorHolmes, M.en
dc.contributor.authorGlanville, A.en
dc.contributor.authorWark, P.en
dc.contributor.authorThompson, P.en
dc.contributor.authorHernandez, P.en
dc.contributor.authorChlumsky, J.en
dc.contributor.authorTeschler, H.en
dc.contributor.authorFicker, J.en
dc.contributor.authorSeersholm, N.en
dc.contributor.authorAltraja, A.en
dc.contributor.authorMäkitaro, R.en
dc.contributor.authorChorostowska-Wynimko, J.en
dc.contributor.authorSanak, M.en
dc.contributor.authorStoicescu, P.en
dc.contributor.authorPiitulainen, E.en
dc.contributor.authorVit, O.en
dc.contributor.authorWencker, M.en
dc.contributor.authorTortorici, M.en
dc.contributor.authoret al.en
dc.identifier.citationLancet Respiratory Medicine, 2017; 5(1):51-60en
dc.description.abstractBACKGROUND: Purified α1 proteinase inhibitor (A1PI) slowed emphysema progression in patients with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which was followed by an open-label extension trial (RAPID-OLE). The aim was to investigate the prolonged treatment effect of A1PI on the progression of emphysema as assessed by the loss of lung density in relation to RAPID-RCT. METHODS: Patients who had received either A1PI treatment (Zemaira or Respreeza; early-start group) or placebo (delayed-start group) in the RAPID-RCT trial were included in this 2-year open-label extension trial (RAPID-OLE). Patients from 22 hospitals in 11 countries outside of the USA received 60 mg/kg per week A1PI. The primary endpoint was annual rate of adjusted 15th percentile lung density loss measured using CT in the intention-to-treat population with a mixed-effects regression model. This trial is registered with, number NCT00670007. FINDINGS: Between March 1, 2006, and Oct 13, 2010, 140 patients from RAPID-RCT entered RAPID-OLE: 76 from the early-start group and 64 from the delayed-start group. Between day 1 and month 24 (RAPID-RCT), the rate of lung density loss in RAPID-OLE patients was lower in the early-start group (-1·51 g/L per year [SE 0·25] at total lung capacity [TLC]; -1·55 g/L per year [0·24] at TLC plus functional residual capacity [FRC]; and -1·60 g/L per year [0·26] at FRC) than in the delayed-start group (-2·26 g/L per year [0·27] at TLC; -2·16 g/L per year [0·26] at TLC plus FRC, and -2·05 g/L per year [0·28] at FRC). Between months 24 and 48, the rate of lung density loss was reduced in delayed-start patients (from -2·26 g/L per year to -1·26 g/L per year), but no significant difference was seen in the rate in early-start patients during this time period (-1·51 g/L per year to -1·63 g/L per year), thus in early-start patients the efficacy was sustained to month 48. INTERPRETATION: RAPID-OLE supports the continued efficacy of A1PI in slowing disease progression during 4 years of treatment. Lost lung density was never recovered, highlighting the importance of early intervention with A1PI treatment. FUNDING: CSL Behring.en
dc.description.statementofresponsibilityNoel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Philip J Thompson … et al.en
dc.rightsCopyright ©2017. Elsevier Inc. All rights reserved.en
dc.subjectRAPID Extension Trial Group; Lung; Humans; Pulmonary Emphysema; alpha 1-Antitrypsin Deficiency; Disease Progression; alpha 1-Antitrypsin; Serine Proteinase Inhibitors; Respiratory Function Tests; Total Lung Capacity; Treatment Outcome; Regression Analysis; Adolescent; Adult; Female; Male; Young Adulten
dc.titleLong-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)en
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.